跳至主要内容
临床试验/JPRN-UMIN000046043
JPRN-UMIN000046043已完成未知

Efficacy and Safety of the BNT162b2, mRNA-1273, and ChAdOx1-S COVID-19 Vaccine in Patients with hematological diseases treated with rituximab or obinutuzumab: An observational study. - Anti-CD20-Ab mRNA COVID19 vaccine study

Kobe City Medical Center General Hospital0 个研究点目标入组 152 人开始时间: 2021年11月11日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
152

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients whom the principal investigator or sub-investigator judges to be inappropriate for participation in the study 2) Patients who have previously received rituximab for non-hematological diseases (polyangiitis granulomatosa, microscopic polyangiitis, refractory nephrotic syndrome) 3) Patients with a history of COVID-19 4) Patients with a history of or coexistence with autoimmune diseases other than chronic idiopathic thrombocytopenic purpura (systemic lupus erythematosus, Sjogren's syndrome, dermatomyositis/polymyositis, mixed connective tissue disease, systemic scleroderma, rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, spondyloarthritis and related diseases, vasculitis syndrome, inflammatory bowel disease, Guillain-Barre syndrome, multiple sclerosis, neuromyelitis optica) 5) Patients who are unable to communicate with others

研究者

相似试验